期刊
JOURNAL OF CELLULAR BIOCHEMISTRY
卷 113, 期 3, 页码 725-734出版社
WILEY
DOI: 10.1002/jcb.23402
关键词
MELANOMA; IMMUNOTHERAPY; CANCER; ANTIBODIES; DENDRITIC CELLS; CTLA-4; T CELLS
资金
- U.S. Department of Agriculture [58-1950-7-707]
- National Institute of Food and Agriculture (NIFA/USDA) [2010-65200-20395]
- NIFA [2010-65200-20395, 581257] Funding Source: Federal RePORTER
Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukin-2, has resulted in prolonged responses in a small subset of patients, providing hope that immunotherapy might be useful for this disease. Ipilimumab, a monoclonal antibody to CTLA-4, was recently approved and a number of other promising investigational approaches are currently being pursued. This manuscript discusses more recent advances in the treatment of melanoma employing a variety of immune-enhancing approaches. J. Cell. Biochem. 113: 725734, 2012. (C) 2011 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据